Comparison of the risks of hospitalisation for cardiovascular events in patients with rheumatoid arthritis treated with tocilizumab and etanercept

Elena Generali, Greta Carrara, Carlo Selmi, Suzanne Verstappen, Antonella Zambon, Alessandra Bortoluzzi, Ettore Silvagni, Carlo Alberto Scirè

Research output: Contribution to journalArticlepeer-review

Abstract

Objective. To verify if tocilizumab (TCZ) is associated with an increased risk of cardiovascular (CV) events compared with etanercept (ETN) in rheumatoid arthritis (RA). Methods. This is a retrospective cohort study on administrative healthcare databases (AHD) in Italy. Patients were identified using a validated algorithm based on AHD. Exposure to specific drugs was estimated by the drug prescription recorded in the AHD. The occurrence of acute CV events (myocardial infarction, stroke, other CV events) was derived from the hospital discharge forms. The association between TCZ or ETN and CV events was estimated using competing risk models, adjusting for pre-specified confounders. Results. We identified 1,752 subjects with RA, 1,086 treated with ETN and 666 with TCZ. TCZ did not increase the overall risk of acute CV events, even when adjusted for pre-specified confounders (hazard ratio HR 0.95, 95% confidence interval 95%CI 0.54-1.66), specifically of acute myocardial infarction (HR 0.39, 95%CI 0.15-1.06), stroke (HR 1.44, 95%CI 0.24-8.68) or other CV event (1.07, 95%CI 0.59-1.92). Conclusion. RA patients with TCZ do not have a medium-term excess of CV risk in patients compared with ETN.

Original languageEnglish
Pages (from-to)310-313
Number of pages4
JournalClinical and Experimental Rheumatology
Volume36
Issue number2
Early online date28 Dec 2017
Publication statusPublished - 18 Apr 2018

Keywords

  • Biological therapy
  • Cardiovascular disease
  • Epidemiology
  • Rheumatoid arthritis

Research Beacons, Institutes and Platforms

  • Manchester Institute for Collaborative Research on Ageing

Fingerprint

Dive into the research topics of 'Comparison of the risks of hospitalisation for cardiovascular events in patients with rheumatoid arthritis treated with tocilizumab and etanercept'. Together they form a unique fingerprint.

Cite this